Q2 EPS Estimate for Vertex Pharmaceuticals Raised by Analyst

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – William Blair upped their Q2 2025 EPS estimates for Vertex Pharmaceuticals in a research note issued on Monday, July 14th. William Blair analyst M. Minter now forecasts that the pharmaceutical company will post earnings per share of $4.00 for the quarter, up from their previous estimate of $3.95. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same quarter last year, the business earned $4.76 EPS. Vertex Pharmaceuticals’s quarterly revenue was up 2.6% compared to the same quarter last year.

A number of other research analysts have also recently issued reports on VRTX. Leerink Partnrs cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 6th. Erste Group Bank cut Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, May 23rd. HC Wainwright reissued a “buy” rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a research note on Monday, June 23rd. JPMorgan Chase & Co. raised their target price on Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Bank of America lifted their price target on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a “buy” rating in a report on Monday, March 31st. Fourteen analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $511.71.

Vertex Pharmaceuticals Stock Down 1.7%

VRTX opened at $464.20 on Tuesday. The firm has a market cap of $119.21 billion, a price-to-earnings ratio of -118.42 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65. The firm’s 50-day simple moving average is $447.43 and its 200-day simple moving average is $461.58. Vertex Pharmaceuticals has a twelve month low of $377.85 and a twelve month high of $519.88.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Activest Wealth Management acquired a new stake in Vertex Pharmaceuticals during the 1st quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Vertex Pharmaceuticals by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 45 shares in the last quarter. Mascagni Wealth Management Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth about $31,000. Flaharty Asset Management LLC bought a new position in shares of Vertex Pharmaceuticals during the 1st quarter valued at about $32,000. Finally, Mpwm Advisory Solutions LLC acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $40,000. Institutional investors own 90.96% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.